Last reviewed · How we verify
JS019
At a glance
| Generic name | JS019 |
|---|---|
| Sponsor | Suzhou Kebo Ruijun Biotechnology Co., Ltd |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study to Evaluate the Safety, Tolerability,JS019 in Patients With Advanced Solid Tumors (PHASE1)
- A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JS019 CI brief — competitive landscape report
- JS019 updates RSS · CI watch RSS
- Suzhou Kebo Ruijun Biotechnology Co., Ltd portfolio CI